Document Detail


Long-term evaluation of indobufen in peripheral vascular disease.
MedLine Citation:
PMID:  1992862     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Indobufen--an inhibitor of platelets aggregation--has been used in 306 patients with intermittent claudication due to peripheral vascular disease. Patients were treated and followed up for one year. One patient of every 3 treated with indobufen was treated with ASA, and a control group of patients receiving no treatment was also followed up. The authors studied by means of a treadmill exercise test the pain-free walking distance (PFWD), the global walking distance (GWD), and the recovery time after exercise. The treatment period was completed by 290 patients: 204 claudicants, 51 claudicants with diabetes, and 35 with a short PFWD and GWD (greater than 150 m). Indobufen was more effective than ASA in improving the PFWD and GWD in all groups. There were also fewer side effects with indobufen, and cardiac morbidity and mortality was also reduced. In conclusion indobufen showed its activity and safety in chronic treatment of patients with peripheral disease, and we suggest that it may be used for long periods without side effects.
Authors:
G Belcaro; P De Simone
Publication Detail:
Type:  Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Angiology     Volume:  42     ISSN:  0003-3197     ISO Abbreviation:  Angiology     Publication Date:  1991 Jan 
Date Detail:
Created Date:  1991-03-14     Completed Date:  1991-03-14     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0203706     Medline TA:  Angiology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  8-14     Citation Subset:  IM    
Affiliation:
Laboratorio di Microcircolazione Cardiovascular Institute Università Abruzzese G.D' Annunzio, Chieti, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aspirin / therapeutic use
Diabetes Complications
Female
Humans
Intermittent Claudication / complications,  drug therapy*,  physiopathology
Isoindoles
Male
Middle Aged
Phenylbutyrates / adverse effects,  therapeutic use*
Platelet Aggregation Inhibitors / adverse effects,  therapeutic use*
Walking
Chemical
Reg. No./Substance:
0/Isoindoles; 0/Phenylbutyrates; 0/Platelet Aggregation Inhibitors; 36690-96-7/indobufen; 50-78-2/Aspirin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  How long can a coronary reperfusion catheter be placed in acute coronary occlusion following failed ...
Next Document:  Total occlusion of the left main coronary artery in a young woman with survival: a case report.